Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAC 88
- Development stage
- Unknown
- Lead developer
- MEDcell
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
VAC 88 is a specialty probiotic product developed and marketed by MEDcell Pharma, primarily indicated for the maintenance of vaginal health and the prevention of recurrent vaginal infections, including bacterial vaginosis and vulvovaginal candidiasis. The formulation typically consists of specific beneficial bacterial strains, such as *Lactobacillus rhamnosus* and *Lactobacillus reuteri*, which are known to colonize the vaginal tract and restore a healthy microbial balance. By producing lactic acid and hydrogen peroxide, these probiotics help maintain an acidic vaginal pH, which inhibits the growth of pathogenic bacteria and yeast. VAC 88 is categorized as a nutraceutical or specialty product within MEDcell's portfolio, which focuses on finished formulations for various therapeutic areas including gynecology, gastroenterology, and cardio-diabetic health.
- Brand names
- VAC 88VAC88VAC-88
Beyond the preview
Go deeper on VAC 88.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAC 88.